Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer
ACS Biomaterials Science & Engineering · 2024
DOI: 10.1021/acsbiomaterials.3c01531 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Biomaterials Science & Engineering, 2024. Verfasst von Pengcheng Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China. Hauptthemen laut MEDLINE: Liposomes, Colorectal Neoplasms, Hereditary Nonpolyposis, Colonic Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Second Affiliated Hospital of Fujian Medical University, Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C.
Abstract (Originalsprache)
Treatment with immune checkpoint inhibitors (ICIs) has shown efficacy in some patients with Lynch syndrome-associated colon cancer, but some patients still do not benefit from it. In this study, we adopted a combination strategy of tumor vaccines and ICIs to maximize the benefits of immunotherapy. Here, we obtained tumor-antigen-containing cell lysate (TCL) by lysing MC38Mlh1 KD cells and prepared liposome nanoparticles (Lipo-PEG) with a typical spherical morphology by thin-film hydration. Anti-PD-L1 was coupled to the liposome surface by the amidation reaction. As observed, anti-PD-L1/TCL@Lipo-PEG was not significantly toxic to mouse intestinal epithelial cells (MODE-K) in the safe concentration range and did not cause hemolysis of mouse red blood cells. In addition, anti-PD-L1/TCL@Lipo-PEG reduced immune escape from colon cancer cells (MC38Mlh1 KD) by the anti-PD-L1 antibody, restored the killing function of CD8+ T cells, and targeted more tumor antigens to bone marrow-derived dendritic cells (BMDCs), which also expressed PD-L1, to stimulate BMDC antigen presentation. In syngeneic transplanted Lynch syndrome-associated colon cancer mice, the combination of anti-PD-L1 and TCL provided better cancer suppression than monoimmunotherapy, and the cancer suppression effect of anti-PD-L1/TCL@Lipo-PEG treatment was even better than that of the free drug. Meanwhile anti-PD-L1/TCL@Lipo-PEG enhanced the immunosuppressive tumor microenvironment. In vivo fluorescence imaging and H&E staining showed that the nanomedicine was mainly retained in the tumor site and had no significant toxic side effects on other major organs. The anti-PD-L1/TCL@Lipo-PEG prepared in this study has high efficacy and good biosafety in alleviating the progression of Lynch syndrome-associated colon cancer, and it is expected to be a therapeutic candidate for Lynch syndrome-associated colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastrointestinal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, China.
ORCID-Profile: Kai Ye
Förderung
- Second Affiliated Hospital of Fujian Medical University
- Key Clinical Specialty Discipline Construction Program of Fujian, P.R.C
Zitieren
APA
Wang, P., Zhong, W., Huang, Q., Zhu, Y., Chen, L., & Ye, K. (2024). Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer. ACS Biomaterials Science & Engineering. https://doi.org/10.1021/acsbiomaterials.3c01531
Vancouver
Wang P, Zhong W, Huang Q, Zhu Y, Chen L, Ye K. Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer. ACS Biomaterials Science & Engineering. 2024. doi:10.1021/acsbiomaterials.3c01531
BibTeX
@article{Wang2024,
author = {Wang, Pengcheng and Zhong, Wenjin and Huang, Qiaozhen and Zhu, Yuejia and Chen, Liquan and Ye, Kai},
title = {Liposome Nanomedicine Based on Tumor Cell Lysate Mitigates the Progression of Lynch Syndrome-Associated Colon Cancer},
journal = {ACS Biomaterials Science & Engineering},
year = {2024},
doi = {10.1021/acsbiomaterials.3c01531}
}
EUVIMED